Your browser is no longer supported. Please, upgrade your browser.
Settings
VSTM Verastem, Inc. daily Stock Chart
VSTM [NASD]
Verastem, Inc.
Index- P/E- EPS (ttm)-1.83 Insider Own6.17% Shs Outstand67.69M Perf Week3.85%
Market Cap548.29M Forward P/E- EPS next Y-0.99 Insider Trans0.26% Shs Float67.69M Perf Month24.04%
Income-75.80M PEG- EPS next Q-0.34 Inst Own20.40% Short Float10.80% Perf Quarter94.24%
Sales- P/S- EPS this Y-79.10% Inst Trans4.15% Short Ratio2.87 Perf Half Y170.00%
Book/sh0.76 P/B10.66 EPS next Y20.40% ROA-107.10% Target Price12.33 Perf Year126.26%
Cash/sh0.95 P/C8.54 EPS next 5Y1.74% ROE-163.60% 52W Range2.77 - 9.07 Perf YTD163.84%
Dividend- P/FCF- EPS past 5Y-0.70% ROI- 52W High-10.69% Beta2.58
Dividend %- Quick Ratio4.40 Sales past 5Y- Gross Margin- 52W Low192.42% ATR0.56
Employees69 Current Ratio4.40 Sales Q/Q- Oper. Margin- RSI (14)64.27 Volatility6.45% 8.00%
OptionableYes Debt/Eq0.39 EPS Q/Q-17.80% Profit Margin- Rel Volume0.70 Prev Close8.24
ShortableYes LT Debt/Eq0.39 EarningsAug 07 AMC Payout- Avg Volume2.55M Price8.10
Recom1.80 SMA206.42% SMA5030.98% SMA20091.66% Volume1,787,469 Change-1.70%
Jul-13-18Initiated BTIG Research Buy $17
May-02-18Initiated Seaport Global Securities Buy $14
Mar-08-18Initiated B. Riley FBR, Inc. Buy $15
Sep-07-17Reiterated H.C. Wainwright Buy $6.50 → $10
Apr-13-17Initiated Oppenheimer Outperform
Mar-24-17Reiterated H.C. Wainwright Buy $5 → $6.50
Sep-29-15Downgrade Raymond James Strong Buy → Outperform
Sep-29-15Downgrade JMP Securities Mkt Outperform → Mkt Perform
Sep-29-15Downgrade Jefferies Buy → Hold
Sep-29-15Downgrade Cantor Fitzgerald Buy → Hold
Sep-28-15Downgrade ROTH Capital Buy → Neutral $23 → $2
Sep-28-15Downgrade Mizuho Buy → Neutral $21 → $2
Sep-09-15Initiated Raymond James Strong Buy
May-12-15Reiterated UBS Buy $30 → $24
Apr-08-15Initiated H.C. Wainwright Buy $16
Jan-23-15Reiterated ROTH Capital Buy $29 → $23
Jul-08-14Resumed Oppenheimer Perform
Feb-11-14Initiated Mizuho Buy $21
Aug-07-13Reiterated UBS Buy $20 → $30
Jul-12-13Reiterated Oppenheimer Outperform $16 → $18
Jul-13-18 08:00AM  Upcoming Catalysts Could Send This Unknown Stock Up 300% or More ACCESSWIRE +5.46%
Jul-06-18 07:45AM  Complimentary Technical Snapshots on Verastem and Three More Biotech Stocks ACCESSWIRE
Jul-05-18 04:05PM  Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jul-02-18 07:00AM  Verastem Oncology to Participate in the Oppenheimer Boston Oncology Insight Summit Business Wire
Jun-25-18 07:00AM  Verastem Oncology to Join Russell 3000® Index Business Wire
Jun-22-18 10:30AM  Biotech's Making Great Progress ACCESSWIRE
Jun-20-18 08:00AM  Verastem Upcoming FDA Review, Big Steps Forward in the Oncology Space ACCESSWIRE
Jun-19-18 08:08AM  Benzinga's Daily Biotech Pulse: Biohaven Sells Right To Drug, Obseva To Sell Shares Benzinga
Jun-18-18 10:20AM  Why Verastem's Stock Is Bolting Higher Today Motley Fool +31.39%
10:00AM  Cancer Stem Cell Company, PPCB Flies Under the Radar ACCESSWIRE
08:20AM  Today's Research Reports on Trending Tickers: Verastem and Nektar Therapeutics ACCESSWIRE
Jun-17-18 04:17PM  2 Clinical-Stage Biotech Stocks That Could Soar Next Week Motley Fool
Jun-16-18 06:30AM  Verastem Oncology Presents Duvelisib Data at EHA 2018 Annual Meeting Business Wire
Jun-15-18 04:35PM  Why Verastem Stock Rocketed Higher Today Motley Fool +17.03%
12:13PM  Is There An Opportunity With Verastem Incs (NASDAQ:VSTM) 36% Undervaluation? Simply Wall St.
09:13AM  Benzinga's Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid Addiction Drug Benzinga
08:25AM  Factors of Influence in 2018, Key Indicators and Opportunity within Companhia Brasileira de Distribuicao, SiteOne Landscape Supply, UGI, Versum Materials, Verastem, and Tanger Factory Outlet Centers New Research Emphasizes Economic Growth GlobeNewswire
08:20AM  Today's Research Reports on Trending Tickers: INSYS Therapeutics and Verastem ACCESSWIRE
Jun-14-18 04:03PM  Verastem Oncology Announces $43.0 Million Offering of Common Stock Business Wire
Jun-05-18 09:14AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga +7.39%
08:05AM  Benzinga's Daily Biotech Pulse: Mylan's Neulasta Biosimilar Approved, Portola's CEO To Retire, Regenxbio To Join S&P SmallCap Index Benzinga
07:46AM  Market Sentiment Around Loss-Making Verastem Inc (NASDAQ:VSTM) Simply Wall St.
07:40AM  Complimentary Technical Snapshots on Viking Therapeutics and Three More Biotech Stocks ACCESSWIRE
03:00AM  Verastem Oncology and Yakult Honsha Co., Ltd. Sign Exclusive License Agreement for the Development and Commercialization of Duvelisib in Japan Business Wire
Jun-04-18 04:05PM  Verastem Oncology Presents Data on Two Lead Drug Candidates at ASCO 2018 Annual Meeting Business Wire
07:00AM  Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
May-25-18 08:30AM  Today's Research Reports on Trending Tickers: Corcept Therapeutics and Verastem ACCESSWIRE -6.11%
May-23-18 04:05PM  Verastem Oncology Announces Closing of Underwriters Option to Purchase Additional Shares Business Wire
May-21-18 04:05PM  Verastem Oncology to Present Scientific Data Supporting Immuno-Oncology Applications of Duvelisib & Defactinib at the 3rd Annual Advances in Immuno-Oncology Congress Business Wire
May-17-18 09:50AM  Verastem Oncology to Present Duvelisib Data at EHA 2018 Annual Meeting Business Wire
May-16-18 05:09PM  Verastem Oncology to Present Data on Two Lead Drug Candidates at ASCO 2018 Annual Meeting Business Wire -12.02%
12:48PM  Why Verastem Stock Is Plunging Today Motley Fool
09:29AM  Verastem Oncology Announces Pricing of Public Offering of Common Stock Business Wire
08:10AM  Benzinga's Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings Benzinga
May-15-18 04:01PM  Verastem Oncology Announces Public Offering of Common Stock Business Wire
May-04-18 04:05PM  Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
May-03-18 05:27PM  Verastem: 1Q Earnings Snapshot Associated Press
04:05PM  Verastem Oncology Reports First Quarter 2018 Financial Results Business Wire
07:00AM  Verastem Oncology Reports on Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma Opportunity, Landscape and Advancements in Pre-Commercial Initiatives at Analyst and Investor Day Business Wire
May-02-18 11:56AM  Boston biotech entrepreneur Christoph Westphal launches new startup American City Business Journals
Apr-23-18 07:00AM  Verastem to Host Analyst and Investor Day on May 2, 2018 Business Wire
Apr-19-18 08:00AM  Analysis: Positioning to Benefit within Verastem, DineEquity, Olin, Quantum, Kimco Realty, and NovoCure Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Apr-13-18 08:37AM  Verastem (VSTM) in Focus: Stock Moves 8% Higher Zacks
Apr-09-18 04:05PM  Verastem Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire +10.81%
11:10AM  Biotech shares soar on dealmaking, drug breakthroughs; AveXis jumps 77 percent CNBC
08:44AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
03:00AM  FDA Accepts New Drug Application for Duvelisib and Grants Priority Review Business Wire
Mar-29-18 07:00AM  Verastem to Present at the H.C. Wainwright Global Life Sciences Conference Business Wire
Mar-16-18 06:36PM  Infinity (INFI) Reports Narrower-than-Expected Loss in Q4 Zacks
Mar-14-18 04:05PM  Verastem Updates Presentation Time for Oppenheimer & Co. Healthcare Conference Business Wire
07:00AM  Verastem to Present at Upcoming Conferences Business Wire
Mar-13-18 07:00AM  Verastem Reports Year-End 2017 Financial Results Business Wire -5.35%
Mar-02-18 04:05PM  Verastem Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Feb-26-18 07:00AM  Verastem to Present at the 30th Annual ROTH Conference Business Wire
Feb-09-18 07:35AM  Research Report Identifies Ichor, TASER International, Premier, NuVasive, Verastem, and BLACKLINE INC with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
07:10AM  Blog Exposure - Verastem Reported Submission of NDA For Duvelisib for Treatment of Patients with Relapsed or Refractory CLL/SLL and Follicular Lymphoma ACCESSWIRE
Feb-07-18 08:30AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:00AM  Verastem Submits New Drug Application to U.S. FDA for Duvelisib for the Treatment of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma Business Wire
Feb-06-18 04:05PM  Verastem Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jan-26-18 02:45PM  Verastem Presents Preclinical Data at ASCO-SITC Highlighting the Synergistic Effects of Duvelisib in Combination with Immune Checkpoint or Co-Stimulatory Antibodies in B Cell Lymphoma Model Business Wire +5.26%
Jan-04-18 04:01PM  Verastem Announces Increased Hercules Debt Facility Business Wire
07:01AM  Verastem Appoints Joseph Lobacki as Chief Commercial Officer Business Wire
Dec-15-17 09:18AM  Verastem Announces Pricing of Public Offering of Common Stock Business Wire -13.97%
07:00AM  3 Stocks to Watch on Friday: DDR Corp (DDR), Hess Corp. (HES) and Verastem Inc (VSTM) InvestorPlace
Dec-14-17 05:07PM  Verastem Announces Public Offering of Common Stock Business Wire
Dec-12-17 08:20AM  Todays Research Reports on Trending Tickers: Array BioPharma and Verastem, Inc. ACCESSWIRE
Dec-11-17 05:00PM  Verastem Announces the Presentation of Phase 1 Duvelisib Combination Data in T-Cell Lymphomas at the ASH 2017 Annual Meeting Business Wire -16.86%
12:07PM  2 Biotech Stocks to Have On Your Radar Into the New Year ACCESSWIRE
07:35AM  Verastem Jumps on Leukemia Drug Study Results Investopedia
Dec-10-17 04:30PM  Verastem Announces Clinical Data from the Pivotal Phase 3 DUO Study: Duvelisib Significantly Improves Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Business Wire
Dec-05-17 07:00AM  Verastem to Present Results from Pivotal Phase 3 DUO Study in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at a Research and Development Event at ASH 2017 Business Wire
Nov-20-17 08:39AM  Options Traders Expect Huge Moves in Verastem (VSTM) Stock Zacks +5.54%
07:55AM  Research Report Identifies Hill-Rom, TASER International, Synchronoss Technologies, NuVasive, Verastem, and Roku with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Nov-08-17 07:00AM  Verastem to Present at Upcoming Investor Conferences Business Wire
Nov-07-17 07:05AM  Verastem reports 3Q loss Associated Press -5.07%
07:00AM  Verastem Reports Third Quarter 2017 Financial Results Business Wire
Nov-02-17 07:30AM  Corporate News Blog - Verastem Announces Plans to Submit NDA Requesting Full Approval of Duvelisib for Treatment of Patients with Relapsed or Refractory CLL/SLL ACCESSWIRE
Nov-01-17 09:25AM  Verastem Announces Data from Phase 3 DUO Study Selected for Oral Presentation at the American Society of Hematology 2017 Annual Meeting Business Wire -9.16%
Oct-31-17 07:00AM  Verastem Announces Regulatory Strategy for Duvelisib New Drug Application Following Guidance from FDA Business Wire
Oct-17-17 07:00AM  Verastem Pays Milestone Payment to Infinity Pharmaceuticals Business Wire
Oct-11-17 04:01PM  Verastem Appoints NgocDiep Le, MD, PhD as Chief Medical Officer Business Wire
Sep-22-17 07:15AM  Verastem to Present at the Cantor Fitzgerald Global Healthcare Conference Business Wire
Sep-07-17 08:00AM  Today's Research Reports on Stocks to Watch: Moleculin Biotech and Verastem ACCESSWIRE
Sep-06-17 11:11AM  Verastem Shares Are Exploding 50% -- Here's Why TheStreet.com +28.13%
10:31AM  Verastem's blood cancer drug succeeds in late-stage trial Reuters
06:15AM  Verastem's blood cancer drug succeeds in late-stage trial Reuters
06:05AM  Verastem Expands Duvelisib Development Program to Include Peripheral T-Cell Lymphoma Business Wire
06:01AM  Verastem Announces Positive Top-line Data from the Pivotal Phase 3 DUO Study in Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Business Wire
Aug-18-17 09:00AM  Implied Volatility Surging for Verastem (VSTM) Stock Options Zacks
Aug-08-17 04:05PM  Verastem Reports Second Quarter 2017 Financial Results Business Wire
Jul-25-17 07:00AM  Verastem Publishes Scientific Data Highlighting Potential Role of FAK Inhibition in Pancreatic and Breast Cancer Business Wire
Jul-13-17 08:10AM  Today's Research Reports on Stocks to Watch: Alder BioPharmaceuticals Inc. and Verastem Inc. Accesswire
Jul-11-17 04:05PM  Verastem Names Julie B. Feder as Chief Financial Officer Business Wire +16.23%
Jul-07-17 08:20AM  Verastem (VSTM) Shows Strength: Stock Adds 42% in Session Zacks
Jun-24-17 10:00AM  Verastem Reports Phase 2 Long-Term Follow-Up Data for Duvelisib in Patients with Double-Refractory Follicular Lymphoma and Small Lymphocytic Lymphoma at the 22nd Congress of the European Hematology Association Business Wire
Jun-07-17 04:05PM  Verastem to Present Long-Term Follow-Up Data from the DYNAMO Study at the 14th International Conference on Malignant Lymphoma Business Wire
Jun-05-17 01:48PM  Notes From ASCO 2017: Tesaro, Amgen, Others Report New Data Benzinga
May-31-17 07:00AM  Verastem to Present at the Jefferies 2017 Global Healthcare Conference Business Wire -11.97%
May-18-17 06:44AM  Verastem Announces Duvelisib Data Presentations at the 22nd Congress of the European Hematology Association Business Wire
May-11-17 08:00AM  Today's Research Reports on Stocks to Watch: Array Biopharma and Verastem Accesswire
Verastem, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K) signaling pathways. The company's lead FAK inhibitor is defactinib, an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. Its defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. The company also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with hematologic cancers through the dual inhibition of PI3K delta and gamma. Its duvelisib is in Phase 3 randomized and late-and mid-stage clinical trials for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, as well as completed the Phase 2 study for the treatment of patients with double-refractory indolent non-Hodgkin lymphoma. The company has license agreements with Infinity Pharmaceuticals, Inc.; and Pfizer, Inc. Verastem, Inc. was founded in 2010 and is headquartered in Needham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bloom Steven H.Chief Strategy OfficerJun 08Buy5.983,00017,9403,500Jun 12 06:58 PM
Lobacki Joseph MExecutive VP & CCOJun 08Buy5.797,70044,5837,700Jun 12 06:58 PM
BARBERICH TIMOTHY JDirectorDec 05Buy3.9560,538239,125130,000Dec 07 04:02 PM